KPS Life Company Profile

Background

Founded in 2010 by David Kelly, KPS Life is a global Functional Service Provider (FSP) specializing in clinical trial outsourcing services for the biopharmaceutical and medical device sectors. The company's mission is to enhance the quality and execution of clinical trials, thereby accelerating the availability of life-changing therapies for patients. Operating across six continents, KPS Life has established itself as a leader in the FSP market by offering customized and scalable solutions that improve clinical trial outcomes while reducing costs and increasing transparency for its clients.

Key Strategic Focus

KPS Life's strategic focus centers on delivering high-quality, efficient, and cost-effective clinical trial services through its FSP model. The company specializes in clinical monitoring, clinical monitoring oversight, clinical trial management, data management, biometrics, and medical writing. By embedding dedicated resources within sponsor teams, KPS Life ensures seamless integration and maintains sponsor control over clinical trials. The company targets pharmaceutical and biotech companies of all sizes, offering services across all phases of clinical trials.

Financials and Funding

In December 2020, KPS Life completed a growth capital raise from LongueVue Capital (LVC) and Adrian Otte. This partnership aimed to recapitalize the business and provide growth capital to support the company's expansion initiatives. Additionally, in February 2021, KPS Life secured senior debt financing with Santander Bank, N.A., further strengthening its financial position.

Technological Platform and Innovation

KPS Life leverages a progressive FSP model that integrates state-of-the-art technologies to enhance clinical trial operations. The company employs advanced tools and platforms to support its services, including clinical monitoring, data management, and biometrics. By deploying these technologies, KPS Life ensures efficient and high-quality execution of clinical trials, setting a new standard in the industry.

Leadership Team

David Kelly – President, Executive Chairman, Founder: With over two decades of executive management experience in clinical development, David founded KPS Life in 2010. His background includes senior roles at Novartis Pharmaceuticals, Wyeth, Amylin Pharmaceuticals, SmithKline Beecham, and Covance. David holds a BA in Biology from Rutgers University and pursued graduate studies in Molecular Biology.

Mark Ridge – Chief Executive Officer: Appointed in October 2024, Mark brings over 25 years of experience in the pharmaceutical industry. Prior to joining KPS Life, he held executive leadership roles at CSL Behring, where he led clinical development operations resulting in five successful product approvals. Mark's expertise includes running clinical trials and working with CROs and FSPs.

George Sawicki – Chief Operating Officer: George joined KPS Life in 2014 and was appointed COO in 2018. His career spans 25 years in the pharmaceutical industry, including roles as Global Head of R&D Procurement for Teva Pharmaceuticals and Cephalon, Inc. George holds a B.S. in Marketing and Management from West Chester University.

Nicole Duffey – Chief Strategy and Growth Officer: Nicole leads Marketing, Business Development, and Proposals & Sales Operations at KPS Life. Her experience includes leadership roles at Johnson & Johnson and ICON, where she managed global FSP operations and strategic solutions. Nicole holds a Bachelor of Science in Nursing from Temple University.

Emanuel Pichlak – Chief Financial Officer: Emanuel oversees KPS Life's financial planning, reporting, and analysis. He has over a decade of experience in investment management, focusing on private equity and equity growth investments. Emanuel holds an MBA from Columbia Business School and an MS in Economics from the University of Lodz.

Dr. Armand Czapliński – General Manager, Europe & Head of Global Clinical Operations: With nearly 30 years of experience in medical and clinical research, Dr. Czapliński obtained his Medical Degree from the University of Warsaw and an MBA from HEC Paris. He has extensive experience in expanding CROs across Europe, APAC, and LATAM.

Ken DeCarlo – Vice President, Global Human Resources: Ken is responsible for developing and executing KPS Life's global human resource strategy. His expertise includes succession planning, talent management, and organizational development.

Dana Durkan – Vice President, Global Recruitment: Dana leads a team of recruiters across the Americas, Europe, and the Asia-Pacific region. She has extensive experience in global recruitment, including roles at Transformative Pharmaceutical Solutions and PRA Health Sciences.

Leadership Changes

In October 2024, KPS Life appointed Mark Ridge as Chief Executive Officer. Mark succeeded David Kelly, who continues to serve as President and Executive Chairman. Mark's appointment reflects the company's commitment to strengthening its leadership team to drive future growth and innovation.

Competitor Profile

Market Insights and Dynamics

The global pharmaceutical market has experienced significant growth, with the total market estimated at approximately $1.6 trillion by the end of 2023. This expansion underscores the increasing demand for efficient and high-quality clinical trial services, positioning FSPs like KPS Life as critical partners in drug development.

Competitor Analysis

KPS Life operates in a competitive landscape alongside several key players:

PAREXEL: A global CRO offering comprehensive drug development and regulatory consulting services.

ICON plc: Provides outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organizations.

PRA Health Sciences: Offers outsourced clinical development and data solution services.

These competitors focus on full-service outsourcing models, whereas KPS Life differentiates itself through its specialized FSP model, emphasizing quality, flexibility, and cost efficiency.

Strategic Collaborations and Partnerships

KPS Life has established strategic partnerships to enhance its service offerings:

Quanticate International Limited: A global biometric clinical research organization, partnering with KPS Life to expand capabilities in clinical operations and monitoring oversight.

CRA Assessments LLC: Collaborated to further develop KPS Life's Clinical Research Associates, ensuring the highest quality monitoring for clients worldwide.

Operational Insights

KPS Life's FSP model offers several competitive advantages:

High Retention Rates: Maintains a 93% retention rate of Clinical Research Associates, ensuring consistency and quality in clinical trial execution.

Experienced Workforce: CRAs average over eight years of experience, contributing to efficient and effective trial management.

Cost Efficiency: Achieves an average of 30% savings on study costs compared to traditional outsourcing models.

These factors position KPS Life as a reliable and cost-effective partner for clinical trial services.

Strategic Opportunities and Future Directions

KPS Life is poised for continued growth by leveraging its strengths in the FSP model. The company aims to expand its global footprint, enhance technological capabilities, and deepen strategic partnerships to meet the evolving needs of the pharmaceutical and biotech industries. By maintaining a focus on quality, flexibility, and cost efficiency, KPS Life is well-positioned to capitalize on emerging opportunities in clinical trial outsourcing.